Defining the role of incretin mimetic therapy in the management of type 2 diabetes

Journal of Family Practice

Volumn 56, Issue 12 SUPPL., 2007, Pages

  Unger, Jeff ^a   Nadeau, Daniel A ^b,c  

^a Diabetes and Headache Intervention Center   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Exeter Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN DERIVATIVE; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; VALSARTAN; VERAPAMIL; VILDAGLIPTIN;

BEDTIME DOSAGE; CLINICAL FEATURE; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; SYMPTOM; TREATMENT PLANNING; WEIGHT GAIN;

BIOMIMETIC MATERIALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FAMILY PRACTICE; HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PEPTIDES; PRIMARY HEALTH CARE; TREATMENT OUTCOME; VENOMS;

EID: 37349021012     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the US. 2005. Atlanta, GA: US Dept. of Health and Human Services, Centers for Disease Control and Prevention; 2005. http://ndep.nih.gov/diabetes/pubs/ 2005_National_Diabetes_Fact_Sheet.pdf. Accessed August 1, 2007.
2. Unger J. Managing mental illness in patients with diabetes. Diabetes Management in Primary Care. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:647-682.
3. Coutinoho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individual followed for 12.4 years. Diabetes Care. 1999;22:233-240.
4. Perkins JM, Davis SN. The rationale for prandial glycemic control in diabetes mellitus. Insulin. 2007;2:52-60.
5. Loew ER, Gray JS, Ivy AC. Is a duodenal hormone involved in carbohydrate metabolism? Am J Physiol. 1940;270:659-663.
6. American Association of Clinical Endocrinologists. Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. Endocrine Practice. 2007;13:1-68.
7. American Diabetes Association. Standards of Medical Care in Diabetes-2007. Diabetes Care. 2007;30:S4-S41.
8. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM. 2005;353:2643-2653.
9. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program [abstract]. Diabetes. 2003;52(suppl 1):A58-59.
10. Buchanan TA, Xiang AH, Peters RK. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51: 2796.
11. Freemark M. Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. J Clin Enocrinol Metab. 2003;88:3-13.
12. Pan XR, Li GW, Hu YH. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 2007;20:537-544.
13. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
14. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
15. Basu A, Shah P, Nielsen M, Basu R, et al. Effects of type 2 diabetes on the regulation of hepatic glucose metabolism. J Invest Med. 2004;52:366-374.
16. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1C. Diabetes Care. 2003;26:881-885.
17. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006;29:435-449.
18. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol. 1981;240:E630-E639.
19. Horowitz M, Edelbroek MA, Wishart JM, et al. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia. 1993;36:857-862.
20. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-830.
21. Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 1991;34:52-54.
22. Baggio LL, Huang Q, Brown TJ, et al. A recombinant human glucagon-like peptide (GLP)-1 albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53:2492-2500.
23. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278:471-478.
24. Pospisilik JA, Stafford SG, Demuth HU, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002;51:943-950.
25. Pospisilik JA, Stafford SG, Demuth HU, et al. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes. 2002;51:2677-2683.
26. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741-750.
27. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
28. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Rept. 2004;117:77-88.
29. Drucker D. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929-2940.
30. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29:139-153.
31. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447.
32. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569.